Tocilizumab for giant cell arteritis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Tocilizumab for Giant Cell Arteritis." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305406/all/Tocilizumab_for_giant_cell_arteritis.
Tocilizumab for giant cell arteritis. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305406/all/Tocilizumab_for_giant_cell_arteritis. Accessed November 3, 2024.
Tocilizumab for giant cell arteritis. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305406/all/Tocilizumab_for_giant_cell_arteritis
Tocilizumab for Giant Cell Arteritis [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2024 November 03]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305406/all/Tocilizumab_for_giant_cell_arteritis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tocilizumab for giant cell arteritis
ID - 1305406
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305406/all/Tocilizumab_for_giant_cell_arteritis
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -